Minerva Neurosciences | NERV

Stock Price
6.63
Daily Change
3.11%
Yearly
1,525.40%
Q2 Forecast
6.44
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Takeda 4,497.00 29.00 0.65% 23.24%
Acadia Pharmaceuticals 24.61 0.71 2.97% 37.49%
Adma Biologics 4.05 0.04 1.00% 101.49%
ALKERMES 29.51 0.23 0.79% 0.68%
AstraZeneca 11,748.00 78.00 0.67% 16.64%
BioCryst Pharmaceuticals 8.35 -0.04 -0.48% -20.10%
Bristol-Myers Squibb 65.66 0.98 1.52% -12.65%
Dynavax Technologies 11.66 0.18 1.57% -3.80%
Esperion Therapeutics 1.36 0.03 2.26% -76.67%
GlaxoSmithKline 1,367.60 20.00 1.48% -19.32%
Halozyme Therapeutics 33.57 1.08 3.32% -26.41%
Ionis Pharmaceuticals 41.75 -1.19 -2.77% 15.49%
J&J 156.97 2.43 1.57% -11.02%
Eli Lilly 442.33 5.84 1.34% 46.64%
Merck & Co 112.52 1.59 1.43% 25.15%
Marinus Pharmaceuticals 7.39 0.17 2.35% 26.32%
Neurocrine Biosciences 92.32 1.13 1.24% -3.37%
Minerva Neurosciences 6.63 0.20 3.11% 1,525.40%
Novartis 90.11 0.74 0.83% 4.99%
Novavax 7.62 -0.10 -1.30% -82.98%
Pfizer 38.36 0.34 0.89% -27.89%
Roche Holding 293.45 0.65 0.22% -8.50%
Sanofi 95.31 0.33 0.35% -4.75%
Vanda Pharmaceuticals 6.06 0.16 2.71% -40.30%

Indexes Price Day Year
USND 13241 139.78 1.07% 10.22%

Minerva Neurosciences

Minerva Neurosciences traded at $6.63 this Friday June 2nd, increasing $0.20 or 3.11 percent since the previous trading session. Looking back, over the last four weeks, Minerva Neurosciences gained 43.51 percent. Over the last 12 months, its price rose by 1,525.40 percent. Looking ahead, we forecast Minerva Neurosciences to be priced at 6.44 by the end of this quarter and at 5.89 in one year, according to Trading Economics global macro models projections and analysts expectations.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101), MIN-301, and seltorexant. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and a adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders. The Company is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD).